Nasdaq
$2.09▼ 0.91%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $649.4MShares out 3.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 10.8After-hours26.10.09 05:074Ownership#●●●
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
James R. Gibson II, an executive at Pacific Biosciences of California, filed a statement of changes in beneficial ownership of securities on October 6, 2026. This Form 4 filing reports the insider's transaction activity regarding the company's stock.…more
$2.09-0.91%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:23144Ownership
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
James R. Gibson II of Pacific Biosciences of California, Inc. (PACB) has filed an SEC Form 144 to report a proposed sale of company securities. This is a standard filing disclosing an insider's plan to dispose of their holdings.…more
$2.09-0.91%vs prev closeView filingShare - 8.19Overnight26.08.19 09:174Ownership
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Mark Van Oene, an executive at Pacific Biosciences (PACB), reported an insider transaction involving company securities on August 17, 2026. This filing serves as the official disclosure of the executive's change in beneficial ownership via Form 4.…more
$2.09-0.91%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 22:05#●●●#●●●#●●●
PacBio and Verily Health Announce Strategic Collaboration for Biomedical AI…more
PacBio has entered a multi-year strategic collaboration with Verily Health to integrate its long-read sequencing technology with Verily's AI-ready data platform. This partnership aims to scale genomic data analysis and enhance the development of AI models for biomedical research.…more
$2.09-0.91%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14After-hours26.10.15 05:05
●●●●●●●● ●●●●● ●●●●●●
PacBio has scheduled its third quarter 2026 financial results announcement for November 4, 2026. Investors will be watching the upcoming conference call for updates on the company's quarterly performance and business outlook.…more
$2.09-0.91%vs prev close - 10.6Pre-market26.10.06 22:06
●●●●●●●● ●●●●● ●●●●●●
PacBio and AI drug discovery firm TychoBio have announced a collaboration to generate full-length RNA data for training RNA therapy design models. TychoBio will utilize PacBio's sequencing technologies to analyze over 10,000 samples to support the development of RNA-targeting compounds.…more
$2.09-0.91%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report